MedTrace Logo

RWE of 1st Line Treatment With ATO/ATRA for Adult APL

NCT04897490 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-01-09

No results posted yet for this study

Summary

This is a multicenter, observational real world clinical trial with prospective follow up that will evaluate the treatment outcome of acute promyelocytic leukemia (APL) patients in the first line with arsenic trioxide and all trans retinoic acid (ATO/ATRA) based regimens in Argentina.

Conditions

  • Promyelocytic Leukemia, Adult Acute

Interventions

OTHER

Evaluation of first line treatment with ATO/ATRA outcome

Evaluation of first line treatment with ATO/ATRA outcome (o event free survival and overall survival and toxicity) in adult patients with APL.

Sponsors & Collaborators

  • Grupo Argentino de Tratamiento de la Leucemia Aguda

    lead OTHER

Principal Investigators

  • María José Mela Osorio, Dr. · Grupo Argentino de Tratamiento de la Leucemia Aguda

  • Isolda Fernández, Dr. · Grupo Argentino de Tratamiento de la Leucemia Aguda

  • Federico Sackmann, Dr. · Grupo Argentino de Tratamiento de la Leucemia Aguda

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2026-07-01
Completion
2026-12-31

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04897490 on ClinicalTrials.gov